Traditional Chinese Medicine in Osteoporosis: from Pathogenesis to Potential Activity

Overview

Journal Front Pharmacol

Date 2024 Apr 17

PMID 38628648

Authors

Gang Cao

Shaoqi Hu

Yan Ning

Xinyue Dou

Chuan Ding

Lu Wang

Zeping Wang

Xianan Sang

Qiao Yang

Jiangnan Shi

Min Hao

Xin Han

Affiliations

Soon will be listed here.

Abstract

Osteoporosis characterized by decreased bone density and mass, is a systemic bone disease with the destruction of microstructure and increase in fragility. Osteoporosis is attributed to multiple causes, including aging, inflammation, diabetes mellitus, and other factors induced by the adverse effects of medications. Without treatment, osteoporosis will further progress and bring great trouble to human life. Due to the various causes, the treatment of osteoporosis is mainly aimed at improving bone metabolism, inhibiting bone resorption, and promoting bone formation. Although the currently approved drugs can reduce the risk of fragility fractures in individuals, a single drug has limitations in terms of safety and effectiveness. By contrast, traditional Chinese medicine (TCM), a characteristic discipline in China, including syndrome differentiation, Chinese medicine prescription, and active ingredients, shows unique advantages in the treatment of osteoporosis and has received attention all over the world. Therefore, this review summarized the pathogenic factors, pathogenesis, therapy limitations, and advantages of TCM, aiming at providing new ideas for the prevention and treatment of OP.

Citing Articles

Syringin protects high glucose-induced BMSC injury, cell senescence, and osteoporosis by inhibiting JAK2/STAT3 signaling.

Zou Y, Gao K, Cao B, He X, Zheng W, Wang X J Appl Biomed. 2025; 22(4):197-207.

PMID: 40033807 DOI: 10.32725/jab.2024.021.

Yigu decoction regulates plasma miRNA in postmenopausal osteoporosis patients: a randomized controlled trial.

Chen H, Zhang R, Li G, Yan K, Wu Z, Zhang Y Front Pharmacol. 2024; 15:1460906.

PMID: 39568587 PMC: 11577086. DOI: 10.3389/fphar.2024.1460906.

References

Forsblad dElia H, Larsen A, Waltbrand E, Kvist G, Mellstrom D, Saxne T . Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis. 2003; 62(7):617-23. PMC: 1754591. DOI: 10.1136/ard.62.7.617. View

Zhang N, Han T, Huang B, Rahman K, Jiang Y, Xu H . Traditional Chinese medicine formulas for the treatment of osteoporosis: Implication for antiosteoporotic drug discovery. J Ethnopharmacol. 2016; 189:61-80. DOI: 10.1016/j.jep.2016.05.025. View

Xie X, Hu L, Mi B, Panayi A, Xue H, Hu Y . SHIP1 Activator AQX-1125 Regulates Osteogenesis and Osteoclastogenesis Through PI3K/Akt and NF-κb Signaling. Front Cell Dev Biol. 2022; 10:826023. PMC: 9014098. DOI: 10.3389/fcell.2022.826023. View

Zhang P, Zhang H, Lin J, Xiao T, Xu R, Fu Y . Insulin impedes osteogenesis of BMSCs by inhibiting autophagy and promoting premature senescence via the TGF-β1 pathway. Aging (Albany NY). 2020; 12(3):2084-2100. PMC: 7041775. DOI: 10.18632/aging.102723. View

Wang J, Yang J, Tang Z, Yu Y, Chen H, Yu Q . Curculigo orchioides polysaccharide COP70-1 stimulates osteogenic differentiation of MC3T3-E1 cells by activating the BMP and Wnt signaling pathways. Int J Biol Macromol. 2023; 248:125879. DOI: 10.1016/j.ijbiomac.2023.125879. View

Wei W, Peng C, Gu R, Yan X, Ye J, Xu Z . Urolithin A attenuates RANKL-induced osteoclastogenesis by co-regulating the p38 MAPK and Nrf2 signaling pathway. Eur J Pharmacol. 2022; 921:174865. DOI: 10.1016/j.ejphar.2022.174865. View

Zhang B, Yuan P, Xu G, Chen Z, Li Z, Ye H . DUSP6 expression is associated with osteoporosis through the regulation of osteoclast differentiation via ERK2/Smad2 signaling. Cell Death Dis. 2021; 12(9):825. PMC: 8413376. DOI: 10.1038/s41419-021-04110-y. View

Wang Y, Cui K, Zhao H, Li D, Wang W, Zhu Y . Bushen Ningxin Decoction pharmacological serum promotes the proliferation and suppresses the apoptosis of murine osteoblasts through MAPK pathway. J Ethnopharmacol. 2009; 122(2):221-6. DOI: 10.1016/j.jep.2009.01.026. View

Zhu N, Hou J . Exploring the mechanism of action Xianlingubao Prescription in the treatment of osteoporosis by network pharmacology. Comput Biol Chem. 2020; 85:107240. DOI: 10.1016/j.compbiolchem.2020.107240. View

10.

Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C . Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med. 2023; 176(2):182-195. DOI: 10.7326/M22-0684. View

11.

Xie Q, Xie J, Dong T, Su J, Cai D, Chen J . Effect of a derived herbal recipe from an ancient Chinese formula, Danggui Buxue Tang, on ovariectomized rats. J Ethnopharmacol. 2012; 144(3):567-75. DOI: 10.1016/j.jep.2012.09.041. View

12.

El-Gazzar A, Hogler W . Mechanisms of Bone Fragility: From Osteogenesis Imperfecta to Secondary Osteoporosis. Int J Mol Sci. 2021; 22(2). PMC: 7826666. DOI: 10.3390/ijms22020625. View

13.

Lee H, Suh J, Kim H, Kim A, Park S, Shin C . Berberine promotes osteoblast differentiation by Runx2 activation with p38 MAPK. J Bone Miner Res. 2008; 23(8):1227-37. DOI: 10.1359/jbmr.080325. View

14.

Lee S, Choi D, Woo E . Inhibition of osteoclast differentiation by tanshinones from the root of Salvia miltiorrhiza bunge. Arch Pharm Res. 2005; 28(8):909-13. DOI: 10.1007/BF02973876. View

15.

Guo Y, Li Y, Xue L, Severino R, Gao S, Niu J . Salvia miltiorrhiza: an ancient Chinese herbal medicine as a source for anti-osteoporotic drugs. J Ethnopharmacol. 2014; 155(3):1401-16. DOI: 10.1016/j.jep.2014.07.058. View

16.

Damerau A, Gaber T, Ohrndorf S, Hoff P . JAK/STAT Activation: A General Mechanism for Bone Development, Homeostasis, and Regeneration. Int J Mol Sci. 2020; 21(23). PMC: 7729940. DOI: 10.3390/ijms21239004. View

17.

Paschou S, Dede A, Anagnostis P, Vryonidou A, Morganstein D, Goulis D . Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. J Clin Endocrinol Metab. 2017; 102(10):3621-3634. DOI: 10.1210/jc.2017-00042. View

18.

Ragipoglu D, Dudeck A, Haffner-Luntzer M, Voss M, Kroner J, Ignatius A . The Role of Mast Cells in Bone Metabolism and Bone Disorders. Front Immunol. 2020; 11:163. PMC: 7025484. DOI: 10.3389/fimmu.2020.00163. View

19.

Mohammad N, Razaly N, Mohd Rani M, Aris M, Effendy N . An Evidence-Based Review: The Effects of Malaysian Traditional Herbs on Osteoporotic Rat Models. Malays J Med Sci. 2019; 25(4):6-30. PMC: 6422536. DOI: 10.21315/mjms2018.25.4.2. View

20.

Qin T, Wu L, Hua Q, Song Z, Pan Y, Liu T . Prediction of the mechanisms of action of Shenkang in chronic kidney disease: A network pharmacology study and experimental validation. J Ethnopharmacol. 2019; 246:112128. DOI: 10.1016/j.jep.2019.112128. View